Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer
Sign Up to like & getrecommendations! Published in 2020 at "Hormones"
DOI: 10.1007/s42000-020-00251-5
Abstract: Purpose Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide,… read more here.
Keywords: new androgen; treatment; prostate cancer; pca ... See more keywords
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.109
Abstract: 109Background: The main treatments for mCRPC are 2 new ART (ABI, ENZA) and 2 taxanes [doctaxel (DOC) and Cabazitaxel]. The optimal sequence is currently not defined. An increasing number of pts are... read more here.
Keywords: enza; versus new; new androgen; androgen receptor ... See more keywords